Palvella Therapeutics

Palvella's lead candidate, Qtorin rapamycin, targets pachyonychia congenita (PC) and Gorlin syndrome (GS) — two rare, autosomal dominant genetic disorders with no FDA-approved therapies. PC causes debilitating calluses, blisters, and cysts on the feet and hands, while GS leads to hundreds of basal-cell carcinomas. Both are driven by mutations that ultimately signal through the mTOR pathway, which rapamycin blocks, creating a shared mechanistic rationale for a single drug across two distinct diseases.

Qtorin is a topical formulation technology designed to deliver rapamycin — a poorly water-soluble mTOR inhibitor — into the skin at therapeutic concentrations without systemic exposure. Standard oral rapamycin is immunosuppressive and requires blood-level monitoring; compounded topical rapamycin in emollients cannot penetrate the skin at doses needed to silence the disease pathway. Palvella's Qtorin rapamycin uses a proprietary anhydrous gel to achieve deep dermal delivery, with clinical data showing rapid reduction in PC callus thickness and basal-cell carcinoma burden in Gorlin patients without systemic immunosuppression.

Palvella is led by founder, President and CEO Wesley H. Kaupinen, who directs corporate and strategic investment decisions and has built the company's pipeline around mTOR pathway biology since 2015. The clinical development is overseen by a chief medical officer and a team experienced in rare-disease trial design partnered with patient foundations like PC Project. As of late 2024, Palvella planned a reverse merger with Pieris Pharmaceuticals to become a public company, which will place capital-allocation decisions under a newly constituted public board.

Palvella is not an investment firm — it is an operating biopharmaceutical company that raises capital directly through venture rounds and public listings to fund its own clinical programs. It does not invest in or manage commitments to external pharmaceutical or biotech investment funds. Its capital deployment is entirely internal, directed at clinical trials, regulatory filings, and commercial preparation for its own pipeline.

Palvella has a long-standing research collaboration with PC Project, a patient advocacy organization that maintains a global registry and natural-history study of pachyonychia congenita. This partnership has enabled Palvella to define the genotype-phenotype map of the disease and use patient-reported outcome measures validated by the PC Project registry as clinical endpoints for the SELVA trial. The relationship is structured as a scientific collaboration, not an ownership stake or a subsidiary arrangement.

Palvella has historically maintained full global rights to Qtorin rapamycin and pursues its own development and commercialization, particularly in the United States. The company has not publicly announced any co-development or licensing partnerships with larger pharmaceutical firms. However, for indications such as Gorlin syndrome — where the patient population is widely distributed — or for ex-U.S. commercialization, a future regional licensing arrangement would be a conventional biotech capital strategy.

Before its 2024 reverse-merger public-listing plan, Palvella raised private venture capital through traditional biotech Series B and Series C syndicates, with investors including Samsara BioCapital and other rare-disease-focused funds. The company did not operate as a family-office affiliated entity or a venture studio spinout — it sourced institutional venture financing from healthcare-specialist funds that understand the multiyear, binary-outcome risk profile of pivotal rare-disease trials.